• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home ENT

Dupilumab linked to improved symptoms in refractory chronic sinusitis and nasal polyposis

byAdarsh ManjunathandMichael Milligan
February 3, 2016
in ENT
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In patients with chronic sinusitis and nasal polyposis refractory to intranasal steroids, dupilumab reduced endscopic nasal polyp burden at 16 weeks follow-up compared to placebo.

2. Patients also had improved radiographic appearance of their polyps, and experienced better quality of life and sense of smell with dupilumab compared to placebo.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Chronic sinusitis plagues many Americans and is characterized by nasal congestion, discharge, postnasal drip, headaches, facial pain, and decreased sense of smell. Current therapies include intranasal and oral steroids, nasal saline irrigation, and antibiotics. Similar immunologic pathways are implicated in chronic sinusitis, asthma, and atopic dermatitis. Thus, the purpose of this study was to determine whether dupilumab, a medication shown to benefit patients with asthma and atopic dermatitis, might also be efficacious in patients with chronic sinusitis. In a randomized, double-blind, placebo-controlled study of 60 adults with chronic sinusitis and nasal polyposis refractory to intranasal steroids, the patients who received dupilumab benefited compared to those given placebo after 16 weeks of follow-up. Specifically, these patients experienced a significant decrease in their endoscopic nasal polyp burden, a decrease in their disease burden on radiographic imaging, improvements in quality of life and daily symptoms, and improvements in sense of smell. Side effects included mild-to-moderate nasopharyngitis, injection site reactions, and headaches.

Overall, this study suggested that for patients with symptomatic chronic sinusitis and nasal polyposis refractory to intranasal steroids, subcutaneous dupilumab injections may decrease nasal polyp burden and improve overall quality of life and daily symptoms without compromising safety. However, future studies will need larger sample sizes than the 60 patients enrolled here, longer than 16 weeks of follow-up to determine long-term effects, and will need to compare dupilumab directly against other therapies rather than placebo.

Click to read the study, published today in JAMA

Relevant Reading: Dupilumab in persistent asthma with elevated eosinophil levels

RELATED REPORTS

Patient Basics: Chronic Sinusitis (in Adults)

Patient Basics: Nasal Polyps

In-Depth [randomized controlled trial]: This study randomized 60 patients with chronic sinusitis and nasal polyposis refractory to intranasal corticosteroid treatment. Patients were enrolled at 13 sites in the U.S. and Europe between 2013 and 2014. In a randomized, double-blind, placebo-controlled study, 30 patients were randomly assigned to dupilumab and 30 patients to placebo. All 60 patients took mometasone furoate nasal spray. The primary endpoint assessed the change in bilateral nasal polyp score on endoscopy after 16 weeks based on polyp size. Additionally, the change in the polyp appearance on imaging using the Lund-Mackay computed tomography score, the patients’ quality of life using the 22-item SinoNasal Outcome Test, and the patient’s sense of smell using the University of Pennsylvania Smell Identification Test (UPSIT) score were all determined. The least squares (LS) mean change in bilateral endoscopic nasal polyp score after 16 weeks of follow-up was -0.3 (95%CI -1.0 to 0.4) in the placebo group and -1.9 (95%CI -2.5 to -1.2) in the dupilumab group (LS mean difference, -1.6; 95%CI -2.4 to -0.7; p < 0.001). The LS mean difference between the 2 groups for the Lund-Mackay computed tomography total score was -8.8 (95%CI -11.1 to -6.6, p < 0.001). Furthermore, patients showed improved quality of life with dupilumab, with the LS mean difference between groups for the 22-item SinoNasal Outcome Test -18.1 (95%CI -25.6 to -10.6, p < 0.001). Finally, patients also showed improved sense of smell as assessed by the UPSIT, with the LS mean difference 14.8 (95%CI 10.9 to 18.7, p < 0.001). Common side effects included nasopharyngitis, injection site reactions, and headaches, with no serious adverse events attributed to dupilumab.

Image: CC/Wiki

©2016 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Chronic SinusitisNasal Polyps
Previous Post

Expiratory central airway collapse associated with poor quality of life

Next Post

Moderate seafood consumption associated with decreased risk of Alzheimer pathology

RelatedReports

Health A to Z

Patient Basics: Chronic Sinusitis (in Adults)

November 30, 2014
Health A to Z

Patient Basics: Nasal Polyps

November 30, 2014
Next Post
Genetic risk assessment for Alzheimer’s disease does not increase anxiety, depression or stress

Moderate seafood consumption associated with decreased risk of Alzheimer pathology

Oral amoxicillin as effective as injectable benzylpenicillin-gentamicin for infants with infection in which referral not possible [AFRINEST Trial]

Antibiotics not linked to improved recovery in acute malnutrition

Past marijuana exposure linked to impaired verbal memory

Past marijuana exposure linked to impaired verbal memory

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Chronic obstructive pulmonary disease associated with worse postoperative outcomes
  • Empagliflozin use is associated with slower progression of chronic kidney disease
  • Diagnostic tool may help identify cerebral palsy regardless of encephalopathy features
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options